Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 10 (October)

1. Gene therapy for BCR-ABL(+) human CML with dual phosphorylation resistant p27(Kip1) and stable RNA interference using an EBV vector.
   J Gene Med, 8(10): 1251-61. [Abstract] [Full-text]
2. Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia.
   Cancer Genet Cytogenet, 170(2): 89-92. [Abstract] [Full-text]
3. Treatment of metastatic sarcoma to the liver with bland embolization.
   Cancer, 107(7): 1617-23. [Abstract] [Full-text]
4. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science.
   J Cell Physiol, 209(3): 659-62. [Abstract] [Full-text]
5. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
   Br J Cancer, 95(7): 775-81. [Abstract] [Full-text]
6. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
   J Clin Invest, 116(10): 2633-42. [Abstract] [Full-text]
7. Gastrointestinal stromal tumor (GIST).
   Ann Oncol, 17: x280-x286. [Abstract] [Full-text]
8. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
   Proc Natl Acad Sci U S A, 103(40): 14907-12. [Abstract] [Full-text]
9. Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.
   J Hepatol, 45(5): 696-703. [Abstract] [Full-text]
10. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Blood, 108(8): 2811-3. [Abstract] [Full-text]
11. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    BJU Int, 98(4): 763-9. [Abstract] [Full-text]
12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Clin Cancer Res, 12(19): 5869-78. [Abstract] [Full-text]
13. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
    Nat Med, 12(10): 1181-4. [Abstract] [Full-text]
14. BNP as a marker of the heart failure in the treatment of imatinib mesylate.
    Cancer Lett, 243(1): 16-22. [Abstract] [Full-text]
15. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
    J Clin Oncol, 24(29): 4764-74. [Abstract] [Full-text]
16. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.
    Oncogene, 25(45): 6140-6. [Abstract] [Full-text]
17. Imatinib mesylate-induced acute hepatitis with autoimmune features.
    Eur J Gastroenterol Hepatol, 18(11): 1235-7. [Abstract] [Full-text]
18. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer.
    Cancer Cell Int, 6: 22. [Abstract] [Full-text]
19. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Leukemia, 20(10): 1767-73. [Abstract] [Full-text]
20. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Ann Hematol, 85(12): 841-7. [Abstract] [Full-text]
21. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Br J Cancer, 95(8): 1013-9. [Abstract] [Full-text]
22. Expression of Tyrosine Kinase Receptors in Malignant Midgut Carcinoid Tumors.
    Neuroendocrinology. [Abstract] [Full-text]
23. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    Lancet, 368(9544): 1329-38. [Abstract] [Full-text]
24. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies.
    Nucl Med Biol, 33(7): 831-40. [Abstract] [Full-text]
25. Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib.
    J Inorg Biochem, 100(11): 1903-6. [Abstract] [Full-text]
26. Pharmacologic treatment for pulmonary arterial hypertension.
    Curr Opin Cardiol, 21(6): 561-8. [Abstract] [Full-text]
27. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Leuk Res, 30(12): 1577-9. [Abstract] [Full-text]
28. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
    Leuk Res, 30(12): 1499-505. [Abstract] [Full-text]
29. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
    Cancer, 107(8): 1898-908. [Abstract] [Full-text]
30. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
    Biochem Pharmacol, 72(10): 1237-45. [Abstract] [Full-text]
31. Biology and management of malignant pleural mesothelioma.
    Eur J Cancer, 42(16): 2706-14. [Abstract] [Full-text]
32. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.
    AJR Am J Roentgenol, 187(5): 1267-73. [Abstract] [Full-text]
33. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
    Leukemia, 20(11): 1989-91. [Abstract] [Full-text]
34. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
    Leukemia, 20(11): 1925-30. [Abstract] [Full-text]
35. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
    Am J Surg Pathol, 30(11): 1389-95. [Abstract] [Full-text]
36. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Clin Cancer Res, 12(20): 6073-8. [Abstract] [Full-text]
37. Emerging drugs in chronic myelogenous leukaemia.
    Expert Opin Emerg Drugs, 11(4): 651-64. [Abstract] [Full-text]
38. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Invest New Drugs, 25(1): 31-40. [Abstract] [Full-text]
39. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
    Langenbecks Arch Surg, 391(6): 615-21. [Abstract] [Full-text]
40. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Cancer, 107(9): 2237-44. [Abstract] [Full-text]
41. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate.
    Eur J Surg Oncol, 32(9): 961-3. [Abstract] [Full-text]
42. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Anticancer Drugs, 17(10): 1223-5. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.